Helping you detect, treat and manage arthritis

Call for patient input on secukinumab for AS and PsA

Megaphone GraphicDo you have ankylosing spondylitis (AS) or psoriatic arthritis (PsA) or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for secukinumab (Cosentyx®) for the treatment of ankylosing spondylitis or psoriatic arthritis. Secukinumab is a fully human monoclonal antibody that targets IL-17A, a protein central to the development of inflammatory diseases. It is given by an injection.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We are calling for input from our members, subscribers and their family members who have ankylosing spondylitis or psoriatic arthritis. Caregivers are also invited to provide input.

We would like to gather your views and share them with the CDR.  Continue reading

Quebec’s INESSS wants to hear your comments

Megaphone GraphicQuebec’s INESSS wants to hear your comments on apremilast (Otezla®) and adalimumab (Humira®) 

Do you have psoriatic arthritis or juvenile arthritis or care for someone who does? We need your valuable input.

The National Institute of excellence in health and social services (INESSS) in Quebec is asking health professionals, consumers and patients, and patient groups to submit their comments about apremilast (Otezla®) for the treatment of psoriatic arthritis and adalimumab (Humira®) for the treatment of juvenile arthritis. These medications are being evaluated as part of the 2016 update to the List of Medications.  Continue reading

AS Health Storylines: An app for your AS journey

Screen grab image of appAS Health Storylines is a self-care app for ankylosing spondylitis (AS) and associated spondyloarthritis diseases. It is developed in partnership with the Canadian Spondylitis Association, and is powered by the Health Storylines™ platform from Self Care Catalysts Inc. The Canadian Spondylitis Association is a national association to advocate for and support those living with ankylosing spondylitis, psoriatic arthritis, and associated spondyloarthritis diseases.

This app is created with input from people with AS so that the right health tools are available to you. The app allows you to record your symptoms, fatigue levels, moods, and more. Choose what you want to track to build your own summary – “My Storylines” –  to learn more about your health, and to share – safely and securely – with your doctor about what happened between visits.

The following health tools in the app will help you better manage and monitor your AS or associated spondyloarthritis disease: Continue reading

CADTH’s Request for Advice on the CDEC’s recommendations for denosumab

Stickman with megaphone calling for patient inputWould you like to provide input to inform CADTH’s report and CDEC’s advice? 

The Canadian Agency for Drugs and Technologies in Health (CADTH) has received a request for advice for denosumab (Prolia®). The request for advice comes from their participating drug plans, and can result in a revised Canadian Drug Expert Committee (CDEC) recommendation or a CDEC Record of Advice.

CADTH is interested in learning:

  1. How should fracture risk be best described?
  2. Is there a place for age (>75 years) or bone density scores, or are these adequately captured within fracture risk?
  3. How should bisphosphonate failure be best described?
  4. How should bisphosphonate intolerance be best described?

Advice is sought regarding the alignment of the CDEC recommendations for women (2011) and for men (2015).   Continue reading

Jobs that put your joints at risk

A construction workerLabour Day celebrates the achievements of workers. It originated with the labour union movement which called for eight hours for work, eight hours for recreation, and eight hours for rest. It is important that we acknowledge workplace safety, especially for your joints, in order to foster workplace achievements, retain qualified workers, and optimize work productivity.

Certain jobs put your joints at higher risk of getting arthritis, such as those that require you to make the same repetitive motions daily. In an interview with Everyday Health, Erik Gail, MD, professor of clinical medicine in the rheumatology section and interim director of the Arizona Arthritis Center at the University of Arizona College of Medicine in Tucson, said: “Anything that puts unhealthy strains or stresses on the joints can cause arthritis.” Below is a list of jobs that may increase your risk for arthritis if you don’t take the necessary arthritis prevention strategies. Continue reading

FDA proposed new naming policies for biosimilar drugs for RA

Yellow and Purple pills in palm of handThe Food and Drug Administration (FDA) has proposed new naming policies for the distinct naming of biosimilars and biologics for rheumatoid arthritis treatment. The new draft guidance is called Nonproprietary Naming of Biological Products: Guidance for Industry and is available to view here.

Under the new policies, which will be designated and enforced by the FDA, separate and distinctive names will be required when it comes to biosimilars and biologic drugs. This will ensure that pharmaceutical companies are following regulations and will remain compliant when it comes to the naming and marketing of biosimilar medications.  Continue reading